Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine

Summary

This is a phase IIb/III, double-blind, randomised, active-controlled, multi-centre, non-inferiority clinical trial that aims to determine safety, tolerability and immunogenicity of a booster vaccination with a recombinant protein receptor binding domain (RBD) fusion homodimer of XBB.1.16 adapted candidate against SARS-CoV-2 developed by HIPRA (PHH-1V81).

Timeline

Start

2023-11-15

Primary completion

2024-06-17

Completion

2024-06-17

Drugs

Indications